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Pharmacometric analyses are complex and multifactorial. It is essential to check, track, and document the vast amounts of
data and metadata that are generated during these analyses (and the relationships between them) in order to comply with
regulations, support quality control, auditing, and reporting. It is, however, challenging, tedious, error-prone, and time-
consuming, and diverts pharmacometricians from the more useful business of doing science. Automating this process would
save time, reduce transcriptional errors, support the retention and transfer of knowledge, encourage good practice, and help
ensure that pharmacometric analyses appropriately impact decisions. The ability to document, communicate, and reconstruct
a complete pharmacometric analysis using an open standard would have considerable benefits. In this article, the Innovative
Medicines Initiative (IMI) Drug Disease Model Resources (DDMoRe) consortium proposes a set of standards to facilitate the
capture, storage, and reporting of knowledge (including assumptions and decisions) in the context of model-informed drug
discovery and development (MID3), as well as to support reproducibility: ‘‘Thoughtflow.’’ A prototype software implementation
is provided.
CPT Pharmacometrics Syst. Pharmacol. (2017) 6, 285–292; doi:10.1002/psp4.12171; published online 20 April 2017.
MOTIVATION
Pharmacometrics (PMx) is a quantitative discipline integrat-
ing pharmacokinetics (PK), pharmacodynamics (PD), phar-
macology, physiology, and statistics to describe and predict
drug disposition and effect in individuals and populations.
PMx models are used to support drug development and
usage by evaluating and simulating drug exposure and
response, by explaining variability in drug response and dis-
position in a study populations, selecting drug doses, opti-
mizing study designs, and describing disease progression.
Model building typically spans multiple phases of develop-
ment and multiple cycles of implementation.1 The typical
PMx analysis process can be represented by a simple
workflow tracking the logical sequence of activities and
decisions necessary for implementing a model-informed
approach.
The underlying structure of and relationships between
each stage in a PMx analysis, the assumptions associated
with these, and the transitions between stages (supported
by decisions) can be highly complex. Figure 1 provides a
detailed illustration of a typical PMx workflow.2 The PMx
analysis consists of a sequence of tasks requiring the inte-
gration of different tools and analysis methods—for
example, preparing/cleaning/merging datasets from various
sources (which might have different formats, and originate
from different databases), performing exploratory analyses,
making assumptions based on those, preparing for estima-
tion (further data manipulation, setting initial estimates,
defining task execution information), estimating parameters
in the model, examining model diagnostics, performing
model validation, testing assumptions made, and collating
all information to make inferences and inform decisions.
Each of these tasks has inputs (data, models, parameter
values, task properties) which produce outputs (estimation
output, graphs, tables, text summary files, etc.) and a
description of the sequence of events (such as run logs)
and dependencies between tasks: the outputs of one task
often provide the inputs for another. There is also an over-
arching workflow that describes the path from initial model
to final model, capturing which “branches” of the develop-
ment “tree” are fruitful in describing the observed data and
which are not. The term “workflow” here speaks as much to
knowledge management as it does to a sequence of tasks
and dependencies.
The challenge any analyst faces is to be able to track
and report these tasks and their interrelationships, as well
as the cognitive process behind them, coherently—a
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process for which we have coined the term “Thoughtflow.” Cap-
turing and summarizing these workflow components is often
performed manually postanalysis; a difficult, tedious, time-
consuming, task fraught with opportunities to introduce errors.
This is made even more complex by the variation in processes
and support infrastructure across different institutions.
Figure 1 Elements of the process of pharmacometric analysis. Based on figure 36.3 from Grasela et al.2 MOA, measures of accept-
ability; SOP, standard operating procedure.
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Capturing the provenance of task outputs (“how was this
output created?”) as well as providing knowledge manage-
ment for the PMx workflow (“how did we get to this mod-
el?”) facilitates reproducibility, “housekeeping,” sharing, and
communicating results with others. It also increases trans-
parency and assists the analyst in constructing a more
robust and objective modeling “story.” The establishment of
firm links between source data, data transformations and
manipulations, final model and simulation code, and conclu-
sions in documentation is crucial in order to facilitate trace-
ability, enabling a third party (such as an independent or
regulatory agency reviewer) to reproduce a complete analy-
sis. It is essential to ensure data integrity, maximize quality
assurance and reproducibility in order to enhance the con-
tribution of model-based methods within the regulatory sub-
mission and review cycle.3
In addition, capturing and reporting provenance informa-
tion is important in supporting compliance with regulatory
expectations of a computer system producing material that
may form part of a regulatory interaction (FDA regulation
21 CFR Part 11).4 A system that can perform this function
will support these regulatory requirements, and will encour-
age transparency of the rationales and details of the work
for communication both internally and externally with regu-
lators and other collaborators.
The Drug Disease Model Resources (DDMoRe) consor-
tium was created to improve the quality, efficiency, and
cost-effectiveness of model-informed drug discovery and
development, a set of concepts, principles, and recommen-
dations that have evolved into what is now termed MID3.3
Among its other activities,5–7 it has also developed a frame-
work for capturing, organizing, and reporting this kind of
provenance information (M.K. Smith, unpublished data).
The concepts and standards we introduce in this article
provide a solid basis for developing standardized software
implementations that can address this unmet need.
State of the art for workflow management tools
There are a range of tools available in the marketplace,
both commercial and open source, for supporting workflows
of executable, computational tasks and tracking the prove-
nance of workflow executions. Taverna,8 KNIME,9 Kepler,10
Activiti (http://activiti.org), Navigator (Mango Solutions,
Chippenham, UK), Improve (scinteco, Vienna, Austria), and
Pipeline Pilot (BIOVIA, San Diego, CA) are some examples.
While these tools are all competent at handling workflows,
noncomputational tasks, such as making inferences and
decisions based on analytical results, are equally important
when tracking and reporting PMx analyses—direct compari-
sons to Thoughtflow are, perhaps, unfair, since the applica-
tions and domains are quite different. It was clear after our
assessment of the available tools that a platform able to
capture computational tasks, business processes, and the
interactions between them was required.
BASIC PRINCIPLES
A provenance-based approach
The Thoughtflow approach is centered on the recording and
exploration of provenance: information about entities, activities,
and agents involved in producing a piece of data—or any other
kind of entity—and the relationships between them.
We use the PROV-O ontology (http://www.w3.org/TR/
prov-o/) as the basis of our approach to defining and captur-
ing provenance information. PROV-O is a World Wide Web
Consortium (W3C) standard that captures the provenance
and relationships between items, as well as an audit trail
information (who did what, when, and how) required of the
Thoughtflow environment. The use of an existing, well-
established standard means that a set of tools for visualizing
relationships are already available, and tools developed by
DDMoRe and its successors are likely to be easily support-
able. Building on an established standard also brings with it
a large body of experience in other applications besides
PMx.
Briefly, the PROV-O ontology defines a series of terms
relating to entities, activities, and agents (Figure 2). An entity
is a physical, digital, conceptual, or other kind of thing with
some fixed aspects, which may be real or imaginary (exam-
ples include a model, a dataset, an output file, a script, a
decision, or an assumption). An activity is something that
occurs over a period of time and acts upon or with entities,
and may encompass consuming, processing, transforming,
modifying, relocating, using, or generating entities (such as
estimating the parameters of a model, or performing a visual
predictive check). Finally, an agent is something that bears
some form of responsibility for an activity taking place, for the
existence of an entity, or for another agent’s activity. An agent
can be an organization, a person, or a software application.
PROV-O defines a set of relationships that describe the
interactions between entities, activities, and agents. Entities
may be derived from other entities (a model based on anoth-
er model), may be generated by activities (a model output
may be generated by an estimation step), and are attributed
to agents (such as NONMEM). Activities may use entities (a
model fit may use a data file), may be informed by other activ-
ities (a previous model development step), and are associat-
ed with agents (NONMEM, or the analyst, or both). Agents
may act on behalf of other agents (NONMEM may be used
by the analyst, and the analyst may be working on behalf of
an organization). PROV-O also supplies the necessary
framework to invalidate entities and/or activities, allowing the
effects of making a change in an analysis to be assessed
based on the relationships of the affected entity or activity
with downstream activities and entities: everything depen-
dent on the change could, for example, be flagged as invalid,
or as requiring reassessment. This has obvious benefits dur-
ing scientific and quality review.
In line with the principles of good practice (GxP), descrip-
tions, rationales, as well as comments for each activity
should be provided in order to identify the key analysis steps
(base and final models, for example), to highlight model
assumptions, and to document rationales and justifications at
decision points. Recording, storing, and querying this infor-
mation has distinct benefits for accurately capturing and
describing how a model was developed, evaluated, and ulti-
mately applied to address a drug development question.
The application of the PROV-O standard to support the
PMx use case necessitated some focus in how entities,
activities, and agents from the PROV-O model were
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described and annotated. There are a number of metadata
items, such as flags or states, that are important to be able
to be attached to entities, such as the importance of an out-
put (“pivotal” or not), its quality control (QC) review status
(“pass” or “fail,” or null if not assessed), and its significance
in the analysis (such as flagging base and final models as
such). Other pieces of metadata related to entities might
include file names and sizes, dates and times of file crea-
tion or most recent modification, details related to the ana-
lyst who created or most recently modified an entity, as well
as version and location control. Metadata for an activity
might include the name of the analysis tool(s) and their ver-
sions, compiler information (if relevant), the command line
used for execution, the hardware and platform on which it
was executed, etc. Metadata for an agent might include
their role in the analysis and within the PMx team.
Transparency in the setting and evaluation of assumptions
that may impact model application is of great importance in
the planning and documentation of any model-informed activ-
ity.3 It was necessary to create a structured definition for
assumptions to enable them to be stored, associated with
other entities or activities, to be peer-reviewed, and to be
reported. Should an assumption change, an analyst could
easily track the components of the model development pro-
cess that depend on that assumption, and reevaluate the rel-
evant steps. In addition, decisions (model selection, based
on outputs from assumption testing, etc.) are crucial to docu-
ment. Decisions were defined as entities that physically take
the form of structured text files containing 1–2 sentences
describing the decision made.
The Thoughtflow specification provides a framework for
querying provenance data to extract, report, and visualize
provenance data associated with an analysis, allowing the
creation of run records, QC and management summaries,
audit trails, and analysis flow diagrams.
Figure 3 shows how these relationships fit together for
different tasks and activities.
IMPACT
The benefits of the proposed Thoughtflow system are mani-
fold. Filtered, interactive views and queries of the data
according to user role (analyst, manager, reviewer) and
appropriate export functionality, in combination with tagging
of entities and activities by analysts to identify key model
development steps, would enable the large amounts of
information typically associated with a PMx analysis to be
reduced to a manageable level, and support the streamlin-
ing of tracking and reporting activities.
Analysts would be able to apply provenance information
to rapidly generate documentation for analyses, from run
records to complete reports, in a reproducible and struc-
tured manner. A well-structured “Thoughtflow” capture and
reporting tool would enhance knowledge sharing and com-
munication among team members: an individual analyst
would be able to rapidly familiarize themselves with an
analysis started by a colleague, or on projects where sever-
al analysts are collaborating, for example. This avoids the
repetition or duplication of prior work and helps assure
quality and reproducibility by ensuring the use of the same
versions of analysis datasets and software.
Using a Thoughtflow-based tool, it would be more straight-
forward for analysts to repeat an analysis either completely
or in part, if required (if source data changed mid-analysis,
for example). Using tagging and appropriate queries, a
Thoughtflow tool could also facilitate the rapid generation of
complete reports (through LaTeX (https://www.latex-project.
org) and support tools such as knitr11) and summary outputs,
such as run logs, model development summaries that include
Figure 2 Entities, activities, agents, and relationships in PROV-O at a high level. See Supplemental Material S1 for definitions of
PROV-O terms endedAtTime, startedAtTime, used, wasAssociatedWith, wasAttributedTo, wasDerivedFrom, wasGeneratedBy, wasInfor-
medBy, actedOnBehalfOf. xsd, XML Schema Definition.
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the source (provenance), version and location of key input
and output files for QC and review purposes, high-level pro-
ject summaries for management, and complete audit trails,
as well as complete reports. This has the added benefit of
avoiding error-prone hand-generated tables.
Objective and detailed summaries of the model develop-
ment process are possible using this approach, including
descriptions of the assumptions being made as well as the
objectives and rationales for individual tasks. This allows
reviewers and regulators to assess precisely what activities
have been completed and evaluate the appropriateness of
the results and conclusions, potentially reducing delays
associated with missing or incomplete information. Additional-
ly, the analysis could be reproduced either completely or in
part if necessary, using a minimal number of steps (key-
strokes or mouse clicks). Standardization of the way the
provenance data are stored, imported, and exported between
applications would facilitate straightforward sharing of data-
bases between analysts and organizations.
Finally, managers would be able follow the process of a
data analysis project at whatever level of detail wished.
Since progress would be updated in real time with respect
to the analysis, this could potentially reduce the time spent
supervising an analyst. It would also be easier to track the
Figure 3 Examples of a provenance approach to pharmacometrics workflow. In (a), entity “model2” is derived from entity “model1” via
activity “clone.” Agent “user1” was associated with the activity. In (b), the parameters of entity “model1” are estimated using entity
“data.csv” during activity “run,” generating a range of new entities including “model1.lst.” Two agents were associated with this activity:
the analyst “user1” and the software “NONMEM.” In (c), entity “model1” is assessed by quality control reviewer “user2” during activity
“QC” to generate a new version of entity “model1,” with the flag qcStatus set to “pass.”
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progress of an analysis with respect to project timelines,
and could thus allow for better resource allocation to meet
timelines.
SPECIFICATIONS AND PROTOTYPE
The proposed DDMoRe Thoughtflow specifications describe
cross-platform, robust support for tracking, reporting, and rep-
licating elements of a modeling and simulation pharmacoki-
netics, pharmacodynamics (PKPD) project (across all phases
of development), either in part or as an entire analysis.
A technical specification for provenance capture and sug-
gestions for implementation has been developed (included as
electronic Supplementary Material) which describes the
input-to-output task workflow, including decisions made, as
well as the PMx knowledge management suitable for describ-
ing a complete, end-to-end modeling and simulation exercise.
Any Thoughtflow solution, in order to be generalizable,
must facilitate the flexible integration of varying operational
processes and standards in industry, small and medium
enterprise, and academia, as well as diverse computational
tools for data handling, visualization, modeling, simulation,
and reporting. Commonly-used tools for data handling and
visualization include R (R Foundation, Vienna, Austria), Mat-
Lab (MathWorks, Natick, MA), SAS (SAS Institute, Cary,
NC), and a myriad of others. Tools used for modeling and
simulation include nonlinear mixed-effects tools such as
NONMEM (ICON, Dublin, Ireland), R, SAS, Phoenix NLME
(Certara, Princeton, NJ), and Monolix (Lixoft, Antony,
France), as well as Bayesian tools such as WinBUGS (MRC
Biostatistics Unit, Cambridge Institute of Public Health, Cam-
bridge, UK), OpenBUGS,12 and Simcyp (Certara). Reports
are typically authored using literate programming tools, such
as Rmarkdown (http://rmarkdown.rstudio.com) and LaTeX/
knitr, or Microsoft Word (Microsoft, Redmond, WA). New
tools such as Stan13 and Julia14 may come into more
common use in the future, hence it will be essential to allow
their integration as well. Owing to the sheer number and
diversity of options available, it is not possible to explicitly
support every tool that can be used for PMx data analyses.
The DDMoRe strategy focuses instead on an application
programming interface (API) for capturing provenance infor-
mation, with prebuilt hooks for a limited number of widely
used tools, such as NONMEM, R, and Monolix. It is none-
theless possible, in principle, to support any tool via the API.
Ultimately, an implementation of the Thoughtflow stand-
ards should facilitate the comprehensive reexecution of
analyses, either completely or in part, based on changes to
key elements in the analysis (such as source data). A tool
should be able to identify dependencies of the changed
object(s), and will allow these to be selectively updated
without the need to completely rerun the entire analysis.
Figure 4 provides a high-level overview of what is pro-
posed, and Figure 5 provides a simple example of how the
components of an analysis are linked with one another.
A software prototype demonstration of how the Thoughtflow
API might be implemented has been developed. Although not
suitable for production use, and lacking some features such
as the ability to reexecute an analysis, it is cross-platform
(supporting all commonly used operating systems) and porta-
ble: it has been designed to provide a basis for further devel-
opment, with a view to a future version being able to be
deployed as painlessly as possible in a range of likely industry,
academic, and regulatory scenarios. It is comprised of several
components: the provenance infrastructure, provenance serv-
ices, a provenance database, a version control system, the
graphical user interface (GUI), and satellite tools allowing
reporting and visualization based on queries of the database.
Provenance infrastructure
The provenance infrastructure monitors user actions and
automates actions such as adding files to the repository. The
infrastructure creates suitable messages and sends them to
Figure 4 Scope of the proposed Thoughtflow approach. GUI, graphical user interface.
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the provenance service, initiating actions such as storing
Thoughtflow information in the provenance database.
Provenance database
In contrast to the traditional relational database approach, a
Resource Description Framework (RDF) triplestore, which
is a “graph” database (a database that uses graph struc-
tures with nodes, edges, and properties to represent and
store data) designed for the storage and retrieval of “triples”
using semantic queries via the RDF format lies at the heart
of the system. A “triple” is a data construct composed of a
subject, a predicate, and an object, and can be visualized
as two nodes linked by a relationship: for example,
“dataset1.csv was created by createData.R,” or “run5.mod
was associated with assumption1.” Thoughtflow information
is captured as a series of interconnected nodes, joined
together by these relationships, which capture all the deci-
sions, activities, inputs, and outputs in a single graph. The
graph can be traversed using semantic queries, matching
on nodes across the graph, using the RDF format. Queries
can return multiple downstream nodes (for example, finding
outputs that are affected by a change to an upstream
input), and support the use of ontologies—a relationship or
node can have subtypes (for instance, both a graph and a
table can be an output of an activity, and can be handled
separately, enabling one to “find graphs” or “find outputs”).
Provenance information will be encoded in the triplestore
using the PROV-O standard. The triplestore is queried via
standard SPARQL queries via a SPARQL server (Apache
Fuseki in our implementation). The prototype uses Apache
Jena (https://jena.apache.org), a free and open source
Java framework for building semantic web and linked data
applications to support the interface with the triplestore.
The prototype was designed with the option to use the
commercial RDF server Virtuoso (OpenLink, Burlington,
MA) in production if so required.
Provenance services
A suite of services will allow a client to query the content of
the provenance database using a simple representational
state transfer (REST) web interface, insulating them from
the underlying implementation and negating the need to
craft their own queries. A request from the client is then
implemented using SPARQL (a semantic query language
for databases: SPARQL Protocol and RDF Query Lan-
guage, https://www.w3.org/TR/rdf-sparql-query). The serv-
ices will support queries to add, update, and retrieve
information—for instance, to determine the provenance of
an entity, to retrieve the information to create a project run
record, or to retrieve a list of invalidated entities and activi-
ties following an update to an upstream entity or activity.
Version control system
It is essential to unambiguously and reproducibly identify all
entities within a project. In order to support this, a dedicat-
ed version control system is necessary. This function is per-
formed in the prototype by Git (https://git-scm.com), a free,
open source, and ubiquitous distributed version control sys-
tem designed to handle everything from small to very large
projects with speed and efficiency.
Graphical user interface
A browser-based GUI has been developed to allow interac-
tive visualization of projects based on Thoughtflow prove-
nance data, and to facilitate simple use of the reporting tools.
Software for reporting and visualization
R can be used to process extracted provenance information
to produce output such as comma separated value (CSV)
data files, publication-ready tables (run records, QC sum-
maries, audit trails, as rich text or LaTeX), and visualizations
(flow charts and trees at varying levels of detail), and scripts
for reexecution of the analysis or parts thereof.
Figure 5 A simple example workflow, showing how various components are linked with one another. QC, quality control; RDF,
Resource Description Framework; SPARQL, SPARQL Protocol and RDF Query Language.
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RECOMMENDATIONS AND ANTICIPATED OUTCOMES
The concepts and standards we have described here, along
with the technical specification and demonstrator tool we
have developed, illustrate DDMoRe’s proposed Thoughtflow
infrastructure. Although the software implementation that
has been developed is a technology demonstration rather
than a production-ready tool, the source code is open and
available under the Affero General Public License, v. 3
(AGPLv3), which allows for its use by third parties provided
derivative works are released under a compatible open
source license. Implementations are already underway in
commercial offerings such as Navigator and Improve. We
anticipate that the work already done will provide a solid
foundation for further development.
The potential for this technology is considerable. We hope
the PROV-O-based standards and general system architec-
ture we have developed will be adopted more widely in the
future, as a platform for documenting, reproducing, and
seamlessly sharing analyses between analysts, teams, com-
panies, regulators, and other stakeholders in a nonpropri-
etary way.
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